Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Promethera Biosciences
Aeglea’s Rare Disease Asset Succeeds At Phase III, In Line To Become First Product
The firm’s lead candidate has shown promise in a pivotal rare disease study, setting it on track for an upcoming BLA catalyst which could lead to Aeglea’s first approved product.
Asia Deal Watch: Promethera Calls On Hao Tian For Asian JV To Advance Its Liver Candidates
Plus recent deals involving BeiGene, Assembly Biosciences, Piramal, Medivant, Revitope, Junshi, JW Therapeutics, Eureka, Acepodia, Chiesi, Bayer, NewG Lab, AnHeart
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program
AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Baliopharm AG
- Promethera Biosciences Japan Branch Ltd
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.